Clinical Trials Logo

Clinical Trial Summary

Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. For severe cases, it was found that aberrant pathogenic T cells and inflammatory monocytes are rapidly activated and then producing a large number of cytokines and inducing an inflammatory storm.Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients with COVID-19.


Clinical Trial Description

COVID-19 has become a urgent and serious public health event that threatens human life and health globally. No specific pharmacological treatments are available to date for COVID-19.Patients contracting the severe form of the disease constitute approximately 15% of the cases which is characterized by extensive acute inflammation. In these severe cases, there will be rapid respiratory system failure.

MSCs have been employed extensively in cell therapy, which includes a plethora of preclinical research investigations as well as a significant number of clinical trials. Safety and efficacy have been shown in many clinical trials. Previous studies have shown that MSCs could significantly reduce inflammatory cell infiltration in lung tissue, reduce inflammation in lung tissue, and significantly improve lung The structure and function of tissues protect lung tissue from damage.The mechanisms underlying the improvements after MSC infusion in COVID-19 patients also appeared to be the robust antiinflammatory activity of MSCs. Recent studies also showed that intravenous MSC infusion could reduce the overactivation of the immune system and support repair by modulating the lung microenvironment after SARS-CoV-2 infection. MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection.

The purpose of this study is to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients With COVID-19.The respiratory function, pulmonary inflammation, clinical symptoms, pulmonary imaging, side effects, immunological characteristics will be evaluated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04346368
Study type Interventional
Source Guangzhou Institute of Respiratory Disease
Contact Shiyue Li, MD
Phone 86-20-83062885
Email lishiyue@188.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date April 2020
Completion date December 2020

See also
  Status Clinical Trial Phase
Completed NCT04516564 - A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects Phase 1
Not yet recruiting NCT04395170 - Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Phase 2/Phase 3
Withdrawn NCT04519424 - CSL324 in COVID-19 Phase 2
Completed NCT05437289 - A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults Phase 1
Completed NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
Withdrawn NCT04848467 - COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older Phase 3
Completed NCT04588363 - COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Terminated NCT04877743 - Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
Completed NCT04742725 - A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19) Phase 2
Completed NCT04375761 - COVID-19: Human Epidemiology and Response to SARS-CoV-2
Completed NCT04545047 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
Completed NCT04378777 - Immunophenotyping Assessment in a COVID-19 Cohort
Completed NCT04327206 - BCG Vaccination to Protect Healthcare Workers Against COVID-19 Phase 3
Terminated NCT05375760 - A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 Phase 2
Completed NCT04344977 - Collection of Anti-SARS-CoV-2 Immune Plasma
Terminated NCT04389840 - Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Phase 2/Phase 3
Withdrawn NCT04425733 - MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) Phase 1
Not yet recruiting NCT04438837 - Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers N/A
Completed NCT04409509 - Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) Phase 2
Completed NCT04275245 - Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia Phase 1/Phase 2